Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7

Brazilian Journal of Medical and Biological Research

Volumn 42, Issue 9, 2009, Pages 854-862

  Cui, D D ^a   Huang, Y ^b   Mao, S H ^b   Chen, S C ^c   Qiu, M ^a   Ji, L L ^b   Yi, C ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c Sichuan Institute of Chinese Materia Medica   (China)

Author keywords

Adriamycin; Apoptosis; Breast cancer; Synergism; TRAIL; TRAIL receptors

Indexed keywords

CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DECOY RECEPTOR 3; DOXORUBICIN; LIPOCORTIN 5; MESSENGER RNA; PROPIDIUM IODIDE; PROTEIN BAX; TETRAZOLIUM; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 71049130311     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2009000900013     Document Type: Article

References (29)

1. Bar-On O, Shapira M, Hershko DD. Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells. Anticancer Drugs 2007; 18: 1113-1121. (Pubitemid 47480736)
2. Rossi D, Baldelli AM, Casadei V, Fedeli SL, Alessandroni P, Catalano V, et al. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer. Anticancer Drugs 2008; 19: 733-737.
3. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26: 3621-3630.
4. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Ozdogan M, Suleymanlar I, et al. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas 2009 (in press).
5. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008; 27: 6207-6215.
6. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000; 275: 23319-23325. (Pubitemid 30646233)
7. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008; 263: 14-25.
8. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001; 61: 1645-1651. (Pubitemid 34292600)
9. Yeh YA, Herenyiova M, Weber G. Quercetin: synergistic action with carboxyamidotriazole in human breast carcinoma cells. Life Sci 1995; 57: 1285-1292.
10. Yoo J, Park SS, Lee YJ. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells. J Cell Biochem 2008; 104: 1636-1646.
11. Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG, et al. The clinical trail of TRAIL. Eur J Cancer 2006; 42: 2233-2240.
12. Koschny R, Walczak H, Ganten TM. The promise of TRAIL - potential and risks of a novel anticancer therapy. J Mol Med 2007; 85: 923-935. (Pubitemid 47282789)
13. Kurbanov BM, Fecker LF, Geilen CC, Sterry W, Eberle J. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 2007; 26: 3364-3377. (Pubitemid 46788891)
14. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
15. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42-49.
16. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12: 228-237. (Pubitemid 40315182)
17. Mendoza FJ, Ishdorj G, Hu X, Gibson SB. Death receptor-4 (DR4) expression is regulated by transcription factor NFkappaB in response to etoposide treatment. Apoptosis 2008; 13: 756-770.
18. Van Valen F, Fulda S, Schafer KL, Truckenbrod B, Hotfilder M, Poremba C, et al. Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer 2003; 107: 929-940. (Pubitemid 37429834)
19. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000; 20: 205-212. (Pubitemid 30002562)
20. McDonald ER III, Chui PC, Martelli PF, Dicker DT, El-Deiry WS. Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. J Biol Chem 2001; 276: 14939-14945. (Pubitemid 37373375)
21. Henson ES, Johnston JB, Gibson SB. The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 2008; 49: 27-35.
22. Burns TF, Bernhard EJ, El-Deiry WS. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001; 20: 4601-4612.
23. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001; 3: 535-546. (Pubitemid 33151020)
24. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004; 64: 5078-5083. (Pubitemid 39006522)
25. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303: 1010-1014. (Pubitemid 38209704)
26. Shinoura N, Sakurai S, Asai A, Kirino T, Hamada H. Caspase-9 transduction overrides the resistance mechanism against p53-mediated apoptosis in U-87MG glioma cells. Neurosurgery 2001; 49: 177-186. (Pubitemid 32552596)
27. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8: 274-281. (Pubitemid 34250106)
28. Jin X, Wu XX, Abdel-Muneem Nouh MA, Kakehi Y. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin. J Urol 2007; 177: 1894-1899. (Pubitemid 46560654)
29. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 2002; 38: 167-176. (Pubitemid 34031833)